Antineoplastics/cetuximab
1
Reactions 1362 - 30 Jul 2011 S Antineoplastics/cetuximab Skin rash and haematological toxicities: 11 case reports A retrospective study identified 11 patients, aged 37–84 years, who developed cetuximab-related skin rashes, and chemotherapy-related haematologic toxicities during treatment for squamous cell carcinoma of the head and neck [see table]. The patients started receiving weekly IV cetuximab given at 400 mg/m 2 for 120 mins, followed by 250 mg/m 2 for 60 min. Additionally, patients were treated with chemotherapy and/or radiotherapy [routes and dosages not stated]. During cetuximab treatment, five patients experienced grade I rash, one patient experienced grade II rash, one patient experienced grade III rash, and two patients experienced grade IV rash [times to reaction onset not stated]. Additionally, chemotherapy-related haematologic toxicities were grade I in four patients, grade II in one patient, grade III in two patients, and grade IV in two patients [times to reaction onset not stated]. At last follow-up, five patients had died due to diease progression [patient outcomes not stated]. Patient characteristics Patient/ Additional Rash Haematological sex/age (y) chemotherapy toxicities 1/M/84 No Grade IV Grade II 2/F/73 Cisplatin Grade III Grade IV 3/M/59 Doxycycline, Grade I Grade I carboplatin 4/F/62 Cisplatin Grade I Grade I 5/M/57 Yes a Grade 0 Grade I 6/M/45 Yes a Grade I Grade I 7/M/53 Yes a Grade II Grade 0 8/M/53 Capecitabine, Grade I Grade IV nedaplatin, gemcitabine, endostatin 9/M/37 No Grade IV Grade 0 10/M/66 Yes a Grade 0 Grade III 11/M/59 Yes a Grade I Grade III a Individual drugs not specified. Xia L-P, et al. Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: A report of 11 cases. Aizheng 28: No. 9, Jan 2009 - China 803058043 1 Reactions 30 Jul 2011 No. 1362 0114-9954/10/1362-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
-
Upload
duonghuong -
Category
Documents
-
view
212 -
download
0
Transcript of Antineoplastics/cetuximab
Reactions 1362 - 30 Jul 2011
SAntineoplastics/cetuximab
Skin rash and haematological toxicities: 11 casereports
A retrospective study identified 11 patients, aged 37–84years, who developed cetuximab-related skin rashes, andchemotherapy-related haematologic toxicities duringtreatment for squamous cell carcinoma of the head andneck [see table].
The patients started receiving weekly IV cetuximab givenat 400 mg/m2 for 120 mins, followed by 250 mg/m2 for60 min. Additionally, patients were treated withchemotherapy and/or radiotherapy [routes and dosages notstated]. During cetuximab treatment, five patientsexperienced grade I rash, one patient experienced grade IIrash, one patient experienced grade III rash, and twopatients experienced grade IV rash [times to reaction onsetnot stated]. Additionally, chemotherapy-relatedhaematologic toxicities were grade I in four patients, gradeII in one patient, grade III in two patients, and grade IV intwo patients [times to reaction onset not stated]. At lastfollow-up, five patients had died due to diease progression[patient outcomes not stated].
Patient characteristicsPatient/ Additional Rash Haematologicalsex/age (y) chemotherapy toxicities
1/M/84 No Grade IV Grade II2/F/73 Cisplatin Grade III Grade IV3/M/59 Doxycycline, Grade I Grade I
carboplatin4/F/62 Cisplatin Grade I Grade I5/M/57 Yesa Grade 0 Grade I6/M/45 Yesa Grade I Grade I7/M/53 Yesa Grade II Grade 08/M/53 Capecitabine, Grade I Grade IV
nedaplatin,gemcitabine,endostatin
9/M/37 No Grade IV Grade 010/M/66 Yesa Grade 0 Grade III11/M/59 Yesa Grade I Grade IIIa Individual drugs not specified.
Xia L-P, et al. Short-term efficacy of cetuximab combined with radiotherapy orchemotherapy on head and neck cancer: A report of 11 cases. Aizheng 28: No. 9,Jan 2009 - China 803058043
1
Reactions 30 Jul 2011 No. 13620114-9954/10/1362-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
